Tag Archive for: Collaboration

Photo credits: Alex Shuper
Collaboration

Angelini partners with Quiver on AI-driven discovery in genetic epilepsies

Italy’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including developmental and epileptic encephalopathies (DEEs). Under the agreement, Quiver could receive up to $120 million in milestone payments plus royalties if Angelini advances drug targets emerging from the collaboration. Financial terms for the upfront payment were not disclosed. Angelini will also receive exclusive access to data generated during the research term.

Read more
Bacteria infection
Collaboration

Basilea strikes up to $48.5m antifungal deal with U.S. biotech Prokaryotics

Swiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive fungal infections, the companies announced on January 7th 2026.

Read more
South San Francisco was pioneering in Biotech. One of those pioneers, Amgen, is also strongly engaged in partnering activities in Europe.Genentech Corp. / Roche
Collaboration

Amgen selects German Disco Pharma to collaborate in multi-million-dollar deal

The new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.

Read more
Glucagon-like peptide-1 (GLP-1) receptor agonist in a tabletNovo Nordisk
Collaboration

Novo Nordisk signs deal for monthly GLP-1 agonist

Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.

Read more
Alessandro Toniolo, CEO of Resalis TherapeuticsResalis/Vimeo
Collaboration

Resalis Therapeutics gets equity investment from Sanofi

Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.

Read more
Quantro used thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAM seq), an orthogonal-chemistry-based RNA sequencing technology that detects 4-thiouridine (s4U) incorporation in RNA species at single-nucleotide resolution, to measure RNA-polymerase-II-dependent gene expression dynamics. © QUANTRO Therapeutics GmbH
Collaboration

Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim

Viennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab.

Read more
Neurosense Therapeutics targets Alzheimer's and Parkinson's Disease but is most advanced in ALS. © Neurosense Therapeutics Ltd
Collaboration

Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd

ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.

Read more
Boehringer Ingelheim headquarters. © Boehringer Ingelheim
Deal

Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.

Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from  Kyowa Kirin Co. Ltd.

Read more
Alfasigma manufacturing plant. © N. Biddau/Alfasigma SpA
Collaboration

Alfasigma SpA signs €170m deal with Galapagos NV

Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.

Read more
Under a high magnification of 10,000X, this digitally-colorized scanning electron microscopic (SEM) image shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture (VISA). © CDC/Janice Haney Carr
Collaboration

LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7

Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.

Read more